Karthik and her team aimed to use CRISPR as a way to identify and isolate a protein generated by the bacteria that cause Lyme ...

Programmable CRISPR tools are turning stem cell biology into something closer to software engineering, shrinking ...

Syntax Bio, a synthetic biology company programming the next generation of cell therapies, has published new research in ...

Chicago-based CRISPR technology company Syntax Bio says it has developed tech which automates the slow, manual process of ...

Syntax Bio, a synthetic biology company programming the next generation of cell therapies, today announced the publication of ...

CRISPR Therapeutics shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 78 to 82.

Syntax Bio, a synthetic biology company programming the next generation of cell therapies, today announced the publication of ...

Revvity targets 2026 growth with multiomics, AI-powered base editing, NGS newborn screening, and immunotherapy advances.

Syntax Bio, a synthetic biology company programming the next generation of cell therapies, today announced it has received an award of up to $856,250 from Breakthrough T1D, the leading global type 1 ...

In the latest allocation of European funding for cutting-edge research, ETH Zurich scientists have performed exceptionally ...

Altair, a global leader in computational intelligence and now part of leading technology company, Siemens, announced the latest updates to HyperWorks® 2026 software. With significant advances in AI, ...

Ark sold shares of Iridium Communications ( IRDM) worth over $14 million with transactions across ARKK, ARKQ and ARKX, ...